A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Latest Information Update: 28 Mar 2025
At a glance
- Drugs Dexamethasone (Primary) ; Prednisolone acetate
- Indications Ocular inflammation; Postoperative inflammation
- Focus Adverse reactions
- Sponsors EyePoint Pharmaceuticals
Most Recent Events
- 25 Mar 2025 Planned End Date changed from 1 Feb 2025 to 1 Feb 2026.
- 25 Mar 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2026.
- 21 Feb 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.